SCHEMBL5456178

SCHEMBL5456178

Cc1cc(S(=O)(=O)N(CC(=O)N(C)C)c2ccc(Cl)cc2Cc2ccccc2Cl)c(C)cc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDFT1 P37268 1/20 0.40
ALDH1A1 P00352 4/20 0.39
THRB P10828 3/20 0.39
POLB P06746 2/20 0.39
LMNA P02545 2/20 0.39
KCNJ6 P48051 1/20 0.39
KCNJ5 P48544 1/20 0.39
KCNJ3 P48549 1/20 0.39
HCRTR2 O43614 2/20 0.37
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
EPHX2 P34913 1/20 0.36
PTGER1 P34995 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
KMT2A Q03164 1/20 0.34
C5AR1 P21730 1/20 0.34
HCRTR1 O43613 1/20 0.34
KEAP1 Q14145 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8273863 0.94 FDFT1 (0.40) FDFT1ALDH1A1THRBPOLBLMNA
SCHEMBL4868968 0.89 FDFT1 (0.38) FDFT1ALDH1A1THRBPOLBLMNA
SCHEMBL14107543 0.89 THRB (0.42) FDFT1ALDH1A1THRBPOLBLMNA
SCHEMBL3250637 0.84 FDFT1 (0.39) FDFT1ALDH1A1THRBPOLBLMNA
SCHEMBL3249343 0.83 PTGER1 (0.39) FDFT1ALDH1A1THRBPOLBLMNA
SCHEMBL8272856 0.83 THRB (0.43) FDFT1ALDH1A1THRBPOLBLMNA
SCHEMBL13357734 0.83 PTGER1 (0.42) FDFT1ALDH1A1THRBPOLBLMNA
SCHEMBL13357749 0.80 THRB (0.36) FDFT1ALDH1A1THRBPOLBLMNA
SCHEMBL3244429 0.79 PTGER1 (0.42) FDFT1ALDH1A1THRBPOLBLMNA
SCHEMBL14107539 0.79 HCRTR2 (0.59) POLBHCRTR2HCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 FDFT1 1608/4885ALDH1A1 2179/4885THRB 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.